KIAA1199 induces advanced biological behavior and development of ovarian cancer through activation of the IL-6/STAT3 pathway

Recently, abnormal expression of KIAA1199 has been detected in Epithelial Ovarian Cancer (EOC). However, the underlined anti-ovarian cancer mechanism of KIAA1199 remains to be enlightened. In our study, we performed to elucidate the effects of KIAA1199 on the advanced biological behavior of EOC cells through activation of the IL-6/STAT3 pathway. Confirmed by immunohistochemistry, KIAA1199 was highly expressed in ovarian borderline and malignant epithelial tumors. A retrospective analysis found that EOC patients with low expression of KIAA1199 had a significantly higher 5-year survival rate than those with high expression. Mechanistically, IL-6 was used to stimulate EOC cells, and the expression of KIAA1199, STAT3 and p-STAT3 increased after IL-6 stimulation. These results could show that KIAA1199 is transcriptionally activated by IL6/STAT3 pathway, thereby accelerating the deterioration of EOC. KIAA1199 could also be used as a poor prognosis factor and potential target in treatment.

[1]  Peng Zhang,et al.  A comprehensive analysis of somatic alterations in Chinese ovarian cancer patients , 2021, Scientific Reports.

[2]  B. Monk,et al.  Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease , 2021, Cancer biology & therapy.

[3]  J. Nemunaitis,et al.  Current Ovarian Cancer Maintenance Strategies and Promising New Developments , 2021, Journal of Cancer.

[4]  S. Mordon,et al.  Microscopic Peritoneal Residual Disease after Complete Macroscopic Cytoreductive Surgery for Advanced High Grade Serous Ovarian Cancer , 2020, Journal of clinical medicine.

[5]  Q. Guo,et al.  Immune Characterization of Ovarian Cancer Reveals New Cell Subtypes With Different Prognoses, Immune Risks, and Molecular Mechanisms , 2020, Frontiers in Cell and Developmental Biology.

[6]  Weimin Deng,et al.  IL-6 promotes nuclear translocation of HIF-1α to aggravate chemoresistance of ovarian cancer cells. , 2020, European journal of pharmacology.

[7]  G. Du,et al.  Serum KIAA1199 is an advanced-stage prognostic biomarker and metastatic oncogene in cholangiocarcinoma , 2020, Aging.

[8]  Chunyan Liu,et al.  Knockout of EGFL6 by CRISPR/Cas9 Mediated Inhibition of Tumor Angiogenesis in Ovarian Cancer , 2020, Frontiers in Oncology.

[9]  Xiawei Wei,et al.  Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy , 2020, Frontiers in Cell and Developmental Biology.

[10]  Yang Zhang,et al.  Downregulation of KIAA1199 by miR‐486‐5p suppresses tumorigenesis in lung cancer , 2020, Cancer medicine.

[11]  M. P. Jammal,et al.  The Role of Stroma in Ovarian Cancer , 2020, Immunological investigations.

[12]  Marie-France Penet,et al.  Ovarian Cancer Targeted Theranostics , 2020, Frontiers in Oncology.

[13]  E. Kohn,et al.  New strategies in ovarian cancer treatment , 2019, Cancer.

[14]  G. Kollias,et al.  STAT3 activation through IL-6/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis , 2019, Gut.

[15]  Y. Okada,et al.  Role of HYBID (Hyaluronan Binding Protein Involved in Hyaluronan Depolymerization), Alias KIAA1199/CEMIP, in Hyaluronan Degradation in Normal and Photoaged Skin , 2019, International journal of molecular sciences.

[16]  Toshio Tanaka,et al.  Targeting Interleukin-6 Signaling in Clinic. , 2019, Immunity.

[17]  R. Brekken,et al.  Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer , 2019, Molecular Cancer.

[18]  Yang Ding,et al.  KIAA1199 promotes invasion and migration in non-small-cell lung cancer (NSCLC) via PI3K-Akt mediated EMT , 2018, Journal of Molecular Medicine.

[19]  Bingxin Chen,et al.  Knockdown of KIAA1199 attenuates growth and metastasis of hepatocellular carcinoma , 2018, Cell Death Discovery.

[20]  Yuan Lu,et al.  New developments in molecular targeted therapy of ovarian cancer. , 2018, Discovery medicine.

[21]  Q. Ye,et al.  Overexpression of KIF2A is Suppressed by miR-206 and Associated with Poor Prognosis in Ovarian Cancer , 2018, Cellular Physiology and Biochemistry.

[22]  Qiong Shen,et al.  KIAA1199 promotes metastasis of colorectal cancer cells via microtubule destabilization regulated by a PP2A/stathmin pathway , 2018, Oncogene.

[23]  Jennifer R. Grandis,et al.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer , 2018, Nature Reviews Clinical Oncology.

[24]  A. Taketomi,et al.  Interleukin‐6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy , 2017, Cancer science.

[25]  Y. Li,et al.  Central Role of CEMIP in Tumorigenesis and Its Potential as Therapeutic Target , 2017, Journal of Cancer.

[26]  M. Götte,et al.  Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways , 2017, Molecular Cancer.

[27]  Thomas A. Sellers,et al.  Epidemiology of ovarian cancer: a review , 2017, Cancer biology & medicine.

[28]  C. A. de la Motte,et al.  Crohn’s Disease Fibroblasts Overproduce the Novel Protein KIAA1199 to Create Proinflammatory Hyaluronan Fragments , 2016, Cellular and molecular gastroenterology and hepatology.

[29]  P. Kroeger,et al.  Pathogenesis and heterogeneity of ovarian cancer , 2016, Current opinion in obstetrics & gynecology.

[30]  S. Rose-John,et al.  The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. , 2015, Current opinion in immunology.

[31]  W. Jiang,et al.  KIAA1199 and its biological role in human cancer and cancer cells (review). , 2014, Oncology reports.

[32]  S. Inoue,et al.  N‐terminal signal sequence is required for cellular trafficking and hyaluronan‐depolymerization of KIAA1199 , 2014, FEBS letters.

[33]  Carolyn Rooth.  Ovarian cancer: risk factors, treatment and management. , 2013, British journal of nursing.

[34]  Y. Doki,et al.  Let-7 Expression Is a Significant Determinant of Response to Chemotherapy through the Regulation of IL-6/STAT3 Pathway in Esophageal Squamous Cell Carcinoma , 2012, Clinical Cancer Research.

[35]  A. Al-Niaimi,et al.  Epithelial ovarian cancer. , 2012, Obstetrics and gynecology clinics of North America.

[36]  Miho Suzuki,et al.  IL-6/IL-6 receptor system and its role in physiological and pathological conditions. , 2012, Clinical science.